X

Trial Profile

An Open-label, Multicenter, Multicohort Phase 1b/2 Clinical Trial of ES101 in Patients With Advanced Malignant Thoracic Tumors

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 03 May 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INBRX 105 (Primary)
Indications Non-small cell lung cancer; Small cell lung cancer; Thoracic neoplasms
Focus Adverse reactions; Therapeutic Use
Sponsors Elpiscience Biopharmaceuticals

Most Recent Events

22 Apr 2022 Planned initiation date changed from 31 Jul 2021 to 1 Jul 2021.
22 Apr 2022 Status changed from not yet recruiting to withdrawn prior to enrolment due to Sponsor's clinical development strategy adjustment.
15 Jul 2021 Planned initiation date changed from 31 May 2021 to 31 Jul 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com